JPM Conference kicks off—CSOP Hang Seng Biotech ETF (03174.HK) and Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) both surge over 3%.

NewTimeSpace—San Francisco, 12 Jan 2026: the 44th J.P. Morgan Healthcare Conference—often dubbed the “pharma Oscars”—opened its doors. Chinese innovators are again out in force: WuXi AppTec, WuXi Biologics and WuXi XDC will take the main-stage podium, joined by BeiGene, Zai Lab, Ascentage and Legend Biotech. Seventeen more—among them Hengrui, Baili Tianheng, 3SBio and RemeGen—will present during the Asia-Pacific track.

By 10:39 a.m. Hong Kong time on 13 Jan the sector had sprinted ahead. CSOP Hang Seng Biotech ETF (03174.HK) and Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) were both up more than 3% (Wind).

Chinaamc Hang Seng Hong Kong Biotech Index ETF（03069.HK）, the first Hong Kong-listed ETF to track the Hang Seng Hong Kong-Listed Biotech Index, retains a scarcity premium in the local market. Its CSOP Hang Seng Biotech ETF (03174.HK) tracks the same benchmark but is engineered for maximum beta, offering high torque to innovators, CXOs, vaccines and gene-therapy names.

Setting the tone, WuXi AppTec guided late Monday to a 2025 net profit of RMB 19.15 bn (+103% YoY) after divestment gains, implying EPS of about RMB 6.70 (+104%).

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.